Bausch Health has beaten EPS estimates in three of its last four reported quarters. Its next test comes after the market closes on October 28. Analysts expect modest year-over-year growth, but recent estimate revisions have moved lower.
Bausch Health Companies Inc. (TSX: BHC) is scheduled to report results for the quarter ended September 30, 2026, after the market closes on October 28. One calendar consensus puts EPS at C$1.19, based on five analysts, and revenue at US$2.73 billion, based on four analysts. Another calendar estimate lists EPS at C$1.24, so the available sources differ on the headline figure. The earnings trend data point to 2.3% year-over-year EPS growth and 1.8% revenue growth. BHC.TO has beaten estimates in three of its last four comparable quarters, but consensus EPS has fallen from C$1.28 30 days ago to C$1.19, with two downward revisions and none upward.
Recent earnings trend
Advertisement
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$3.38B
52W high
$11.08
52W low
$6.10
1W change
+1.22%
Beta
0.37
Analyst Price Targets
Based on analyst covering BHC · as of Sep 17, 2026
Wall Street analysts forecast BHC stock price to fall 22.9% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
-22.9% Upside
Current Price
C$9.09
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
34.9%
Annualized
90-Day Vol
65.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$10.80
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.58 | C$8.50 – C$10.81 |
| 60 trading days | C$10.17 | C$8.58 – C$12.06 |
| 90 trading days | C$10.80 | C$8.77 – C$13.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Analyst coverage: 5 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-10-28 | — | 1.2400 | — |
| 2026-06-30 | 2026-07-29 | 1.2600 | 1.0100 | +24.8% |
| 2026-03-31 | 2026-04-29 | 0.7800 | 0.6900 | +13.0% |
| 2025-12-31 | 2026-02-18 | 1.1000 | 1.2100 | -9.1% |
| 2025-09-30 | 2025-10-29 | 1.1600 | 1.0600 | +9.4% |
| 2025-06-30 | 2025-07-30 | 0.9100 | 0.9400 | -3.2% |
Advertisement
Investor takeaway: The October 28 report will show whether Bausch Health can maintain its recent earnings momentum and meet a modest growth forecast. In a preliminary update on October 12, the company said it expects to raise its full-year 2026 adjusted EBITDA guidance, citing strong third-quarter performance and an expected stronger remainder of the year. That’s encouraging, but investors will still need to assess the reported revenue and earnings, along with management’s outlook. Canadian investors should also consider the company’s negative trailing EPS and profit margin alongside its recent run of quarterly estimate beats.
C$1.19 EPS consensus—and a C$1.24 calendar estimate
The earnings-trends source puts consensus EPS at C$1.19, based on five analysts. A separate calendar estimate lists C$1.24. The trend estimate implies 2.3% growth from year-ago EPS of C$1.16, but it has fallen from C$1.28 over the past month. Revenue consensus is US$2.73 billion, with estimated growth of 1.8%.
Bull case
Bausch Health beat EPS estimates in three of its last four reported quarters, including a 24.75% surprise in the June 2026 quarter. In its October 12 preliminary update, the company pointed to strong third-quarter performance and said it expects to raise full-year adjusted EBITDA guidance. It also recently announced expanded public reimbursement for PrOKEDI in seven provinces and several federal drug plans, which could improve access to the treatment. These developments support the case for continued operating progress, though the reimbursement news doesn’t specify how much revenue it could add.
Bear case
Analysts have lowered their expectations: the trend estimate fell from C$1.28 to C$1.19 over 30 days, with two downward revisions. Bausch Health missed estimates in the December 2025 quarter. Its fundamentals snapshot also shows trailing EPS of -C$4.08 and a -10.12% profit margin. Analyst targets point to caution as well: the average target is C$7.01, compared with a last close of C$9.09. The preliminary guidance update is forward-looking and could change when the company reports. The supplied calendar estimates also differ, listing EPS at either C$1.19 or C$1.24.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
